0000880771-16-000210.txt : 20161115 0000880771-16-000210.hdr.sgml : 20161115 20161115161742 ACCESSION NUMBER: 0000880771-16-000210 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161111 FILED AS OF DATE: 20161115 DATE AS OF CHANGE: 20161115 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blobel Friedhelm CENTRAL INDEX KEY: 0001363213 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 161999888 MAIL ADDRESS: STREET 1: 950 TOWER LANE, SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 certent-form4.xml PRIMARY DOCUMENT X0306 4 2016-11-11 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001363213 Blobel Friedhelm 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 1 1 0 0 President & CEO Common Stock 2016-11-11 4 M 0 5301 1.81 A 92085 D Common Stock 2016-11-11 4 S 0 5301 10.0078 D 86784 D Common Stock 2016-11-14 4 M 0 24699 1.81 A 111483 D Common Stock 2016-11-14 4 S 0 24699 10.3278 D 86784 D Non-Qualified Stock Option (right to buy) 1.81 2016-11-11 4 M 0 5301 0 D 2018-03-18 Common Stock 5301 204699 D Non-Qualified Stock Option (right to buy) 1.81 2016-11-14 4 M 0 24699 0 D 2018-03-18 Common Stock 24699 180000 D The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016. Includes 404 shares purchased under the Issuer's Employee Stock Purchase Plan on August 31, 2016. Granted under the Issuer's 2005 Equity Incentive Plan. 1/36th of such shares will vest on June 1, 2010 and 1/36th will vest monthly thereafter over a three-year period, provided the reporting person remains employed by the Company. /s/ Friedhelm Blobel 2016-11-15